Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR

B.Riley/FBR analyst Harshita Polishetty lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $26.00 (from $40.00) while maintaining a Buy rating following 4Q report.

On the earnings call, management noted that the company has currently decided to defer the advancement of the entinostat-PD-1 combination program, which includes the previously announced ENCORE 607 registration trial in non-small cell lung cancer (NSCLC).

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results